Alnylam Patent Upheld by EPO | GenomeWeb

Alnylam Patent Upheld by EPO


Alnylam Pharmaceuticals last week announced that the European Patent Office's board of appeals ruled that claims within one of the company's core patents meet the mandatory requirements under European patent law.

The patent, EP 1214945, claims methods, medicaments, and uses of siRNAs with a double-stranded structure consisting of 15 to 49 nucleotides, according to Alnylam. It is part of the so-called Kreutzer-Limmer patent family.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.